Sol J Barer - Net Worth and Insider Trading

Sol J Barer Net Worth

The estimated net worth of Sol J Barer is at least $167 Million dollars as of 2024-11-13. Sol J Barer is the Director of Celgene Corp and owns about 1,506,946 shares of Celgene Corp (CELG) stock worth over $163 Million. Sol J Barer is the Director of Teva Pharmaceutical Industries Ltd and owns about 220,442 shares of Teva Pharmaceutical Industries Ltd (TEVA) stock worth over $4 Million. Sol J Barer is also the Director of Amicus Therapeutics Inc and owns about 45,000 shares of Amicus Therapeutics Inc (FOLD) stock worth over $472,050. Besides these, Sol J Barer also holds PDS Biotechnology Corp (PDSB) , NexImmune Inc (NEXI) , ContraFect Corp (CFRXQ) , Aevi Genomic Medicine Inc (GNMX) . Details can be seen in Sol J Barer's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Sol J Barer has not made any transactions after 2023-03-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Sol J Barer

Sol J Barer Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Sol J Barer owns 10 companies in total, including Teva Pharmaceutical Industries Ltd (TEVA) , Avalo Therapeutics Inc (AVTX) , and ContraFect Corp (CFRXQ) among others .

Click here to see the complete history of Sol J Barer’s form 4 insider trades.

Insider Ownership Summary of Sol J Barer

Ticker	Comapny	Transaction Date	Type of Owner
TEVA	Teva Pharmaceutical Industries Ltd	2019-06-04	director
AVTX	Avalo Therapeutics Inc	2020-02-03	director
CFRXQ	ContraFect Corp	2017-07-25	director
		2020-02-03	director
		2016-06-21	director
		2012-11-16	director
		2016-11-29	director
		2013-03-15	director
		2013-11-01	director & 10 percent owner & Chairman of the Board
		2023-07-05	director

Sol J Barer Latest Holdings Summary

Sol J Barer currently owns a total of 7 stocks. Among these stocks, Sol J Barer owns 1,506,946 shares of Celgene Corp (CELG) as of January 13, 2011, with a value of $163 Million and a weighting of 97.39%. Sol J Barer owns 220,442 shares of Teva Pharmaceutical Industries Ltd (TEVA) as of June 4, 2019, with a value of $4 Million and a weighting of 2.25%. Sol J Barer also owns 45,000 shares of Amicus Therapeutics Inc (FOLD) as of March 15, 2013, with a value of $472,050 and a weighting of 0.28%. The other 4 stocks PDS Biotechnology Corp (PDSB) , NexImmune Inc (NEXI) , ContraFect Corp (CFRXQ) , Aevi Genomic Medicine Inc (GNMX) have a combined weighting of 0.08% among all his current holdings.

Latest Holdings of Sol J Barer

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CELG	Celgene Corp	2011-01-13	1,506,946	108.24	163,111,835
TEVA	Teva Pharmaceutical Industries Ltd	2019-06-04	220,442	17.11	3,771,763
FOLD	Amicus Therapeutics Inc	2013-03-15	45,000	10.49	472,050
PDSB	PDS Biotechnology Corp	2015-10-06	32,277	2.96	95,540
NEXI	NexImmune Inc	2023-03-30	164,096	0.22	36,282
CFRXQ	ContraFect Corp	2017-07-25	1,020	0.00	0
GNMX	Aevi Genomic Medicine Inc	2019-12-05	0	0.17	0

Holding Weightings of Sol J Barer

Sol J Barer Form 4 Trading Tracker

According to the SEC Form 4 filings, Sol J Barer has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the sale of 150,400 shares on January 13, 2011, which brought Sol J Barer around $4 Million.

According to the SEC Form 4 filings, Sol J Barer has made a total of 0 transactions in Teva Pharmaceutical Industries Ltd (TEVA) over the past 5 years. The most-recent trade in Teva Pharmaceutical Industries Ltd is the acquisition of 104,500 shares on June 4, 2019, which cost Sol J Barer around $1 Million.

According to the SEC Form 4 filings, Sol J Barer has made a total of 0 transactions in Amicus Therapeutics Inc (FOLD) over the past 5 years. The most-recent trade in Amicus Therapeutics Inc is the acquisition of 25,000 shares on March 15, 2013, which cost Sol J Barer around $85,000.

More details on Sol J Barer's insider transactions can be found in the Insider Trading History of Sol J Barer table.

Insider Trading History of Sol J Barer

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Sol J Barer Trading Performance

GuruFocus tracks the stock performance after each of Sol J Barer's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Sol J Barer is -16.17%. GuruFocus also compares Sol J Barer's trading performance to market benchmark return within the same time period. The performance of stocks bought by Sol J Barer within 3 months outperforms 3 times out of 18 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Sol J Barer's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Sol J Barer

Average Return

Average return per transaction

Outperforming Transactions

5 out of 18 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-3.8
Relative Return to S&P 500(%)	-4.55

Sol J Barer Ownership Network

Ownership Network List of Sol J Barer

No Data

Ownership Network Relation of Sol J Barer

Sol J Barer Owned Company Details

What does Teva Pharmaceutical Industries Ltd do?

Who are the key executives at Teva Pharmaceutical Industries Ltd?

Sol J Barer is the director of Teva Pharmaceutical Industries Ltd. Other key executives at Teva Pharmaceutical Industries Ltd include Exec. VP & European Commercial Richard Daniell , EVP & Business Development Angus Grant , and See "Remarks" Eric A Hughes .

Teva Pharmaceutical Industries Ltd (TEVA) Insider Trades Summary

Over the past 18 months, Sol J Barer made no insider transaction in Teva Pharmaceutical Industries Ltd (TEVA). Other recent insider transactions involving Teva Pharmaceutical Industries Ltd (TEVA) include a net sale of 263,933 shares made by Richard Daniell , a net sale of 130,384 shares made by Eric A Hughes , and a net sale of 61,882 shares made by Amir Weiss .

In summary, during the past 3 months, insiders sold 0 shares of Teva Pharmaceutical Industries Ltd (TEVA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,467,557 shares of Teva Pharmaceutical Industries Ltd (TEVA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,467,557 shares.

Teva Pharmaceutical Industries Ltd (TEVA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Teva Pharmaceutical Industries Ltd Insider Transactions

No Available Data

What does Avalo Therapeutics Inc do?

Who are the key executives at Avalo Therapeutics Inc?

Sol J Barer is the director of Avalo Therapeutics Inc. Other key executives at Avalo Therapeutics Inc include director & 10 percent owner Armistice Capital Master Fund Ltd. , 10 percent owner Caissa Capital Management Ltd. , and Interim CFO Christopher Ryan Sullivan .

Avalo Therapeutics Inc (AVTX) Insider Trades Summary

Over the past 18 months, Sol J Barer made no insider transaction in Avalo Therapeutics Inc (AVTX). Other recent insider transactions involving Avalo Therapeutics Inc (AVTX) include a net purchase of 74,840 shares made by Caissa Capital Management Ltd. , a net sale of 3,683,542 shares made by Armistice Capital Master Fund Ltd. , and a net purchase of 4,000 shares made by Garry Arthur Neil .

In summary, during the past 3 months, insiders sold 0 shares of Avalo Therapeutics Inc (AVTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 15,348 shares of Avalo Therapeutics Inc (AVTX) were sold and 331 shares were bought by its insiders, resulting in a net sale of 15,017 shares.

Avalo Therapeutics Inc (AVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avalo Therapeutics Inc Insider Transactions

No Available Data

What does ContraFect Corp do?

Who are the key executives at ContraFect Corp?

Sol J Barer is the director of ContraFect Corp. Other key executives at ContraFect Corp include VP Finance Michael Messinger , General Counsel Natalie Bogdanos , and Chief Medical Officer Cara M Cassino .

ContraFect Corp (CFRXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ContraFect Corp (CFRXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ContraFect Corp (CFRXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ContraFect Corp (CFRXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

ContraFect Corp Insider Transactions

No Available Data

What does Aevi Genomic Medicine Inc do?

Who are the key executives at Aevi Genomic Medicine Inc?

Sol J Barer is the director of Aevi Genomic Medicine Inc. Other key executives at Aevi Genomic Medicine Inc include director & Chief Executive Officer Michael F Cola , Chief Scientific Officer Garry Arthur Neil , and 10 percent owner Plc Astrazeneca .

Aevi Genomic Medicine Inc (GNMX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aevi Genomic Medicine Inc (GNMX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aevi Genomic Medicine Inc (GNMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aevi Genomic Medicine Inc (GNMX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aevi Genomic Medicine Inc Insider Transactions

No Available Data

What does PDS Biotechnology Corp do?

Who are the key executives at PDS Biotechnology Corp?

Sol J Barer is the director of PDS Biotechnology Corp. Other key executives at PDS Biotechnology Corp include Senior VP & General Counsel Spencer D. Brown , Chief Financial Officer Matthew C Hill , and director & 10 percent owner Delyle W Bloomquist .

PDS Biotechnology Corp (PDSB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PDS Biotechnology Corp (PDSB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PDS Biotechnology Corp (PDSB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PDS Biotechnology Corp (PDSB)'s detailed insider trading history can be found in Insider Trading Tracker table.

PDS Biotechnology Corp Insider Transactions

No Available Data

What does InspireMD Inc do?

Who are the key executives at InspireMD Inc?

Sol J Barer is the director of InspireMD Inc. Other key executives at InspireMD Inc include EVP Clinical/Medical Affairs Patrick Verta , Chief Operating Officer Andrea Tommasoli , and VP Global Marketing Shane Thomas Gleason .

InspireMD Inc (NSPR) Insider Trades Summary

Over the past 18 months, Sol J Barer made no insider transaction in InspireMD Inc (NSPR). Other recent insider transactions involving InspireMD Inc (NSPR) include a net purchase of 50,000 shares made by Gary S Roubin ,

In summary, during the past 3 months, insiders sold 0 shares of InspireMD Inc (NSPR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of InspireMD Inc (NSPR) were sold and 50,000 shares were bought by its insiders, resulting in a net purchase of 50,000 shares.

InspireMD Inc (NSPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

InspireMD Inc Insider Transactions

No Available Data

What does Aegerion Pharmaceuticals Inc do?

Who are the key executives at Aegerion Pharmaceuticals Inc?

Sol J Barer is the director of Aegerion Pharmaceuticals Inc. Other key executives at Aegerion Pharmaceuticals Inc include director & Chief Executive Officer Mary T Szela , other: See Remarks Gregory D Perry , and General Counsel and Secretary Benjamin Harshbarger .

Aegerion Pharmaceuticals Inc (AEGR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aegerion Pharmaceuticals Inc (AEGR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aegerion Pharmaceuticals Inc (AEGR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aegerion Pharmaceuticals Inc (AEGR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aegerion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Amicus Therapeutics Inc do?

Who are the key executives at Amicus Therapeutics Inc?

Sol J Barer is the director of Amicus Therapeutics Inc. Other key executives at Amicus Therapeutics Inc include director & President and CEO Bradley L Campbell , director & Executive Chairman John F Crowley , and Chief People Officer David Michael Clark .

Amicus Therapeutics Inc (FOLD) Insider Trades Summary

Over the past 18 months, Sol J Barer made no insider transaction in Amicus Therapeutics Inc (FOLD). Other recent insider transactions involving Amicus Therapeutics Inc (FOLD) include a net sale of 232,762 shares made by Bradley L Campbell , a net sale of 333,235 shares made by John F Crowley , and a net sale of 95,000 shares made by Ellen Rosenberg .

In summary, during the past 3 months, insiders sold 30,401 shares of Amicus Therapeutics Inc (FOLD) in total and bought 0 shares, with a net sale of 30,401 shares. During the past 18 months, 803,781 shares of Amicus Therapeutics Inc (FOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 803,781 shares.

Amicus Therapeutics Inc (FOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Amicus Therapeutics Inc Insider Transactions

No Available Data

What does CervoMed Inc do?

Who are the key executives at CervoMed Inc?

Sol J Barer is the director & 10 percent owner & Chairman of the Board of CervoMed Inc. Other key executives at CervoMed Inc include GC & Secretary William Robert Elder , director & 10 percent owner Sylvie Gregoire , and Chief Financial Officer John William Tanner .

CervoMed Inc (CRVO) Insider Trades Summary

Over the past 18 months, Sol J Barer made no insider transaction in CervoMed Inc (CRVO). Other recent insider transactions involving CervoMed Inc (CRVO) include a net purchase of 1,000 shares made by William Robert Elder ,

In summary, during the past 3 months, insiders sold 0 shares of CervoMed Inc (CRVO) in total and bought 1,000 shares, with a net purchase of 1,000 shares. During the past 18 months, 0 shares of CervoMed Inc (CRVO) were sold and 1,000 shares were bought by its insiders, resulting in a net purchase of 1,000 shares.

CervoMed Inc (CRVO)'s detailed insider trading history can be found in Insider Trading Tracker table.

CervoMed Inc Insider Transactions

No Available Data

What does NexImmune Inc do?

Who are the key executives at NexImmune Inc?

Sol J Barer is the director of NexImmune Inc. Other key executives at NexImmune Inc include VP & Corporate Controller Timothy Stover , Chief Science Officer Mathias Oelke , and Chief Operating Officer Kristi Jones .

NexImmune Inc (NEXI) Insider Trades Summary

Over the past 18 months, Sol J Barer made no insider transaction in NexImmune Inc (NEXI). Other recent insider transactions involving NexImmune Inc (NEXI) include a net sale of 7,825 shares made by Alan S. Roemer ,

In summary, during the past 3 months, insiders sold 0 shares of NexImmune Inc (NEXI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,825 shares of NexImmune Inc (NEXI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 7,825 shares.

NexImmune Inc (NEXI)'s detailed insider trading history can be found in Insider Trading Tracker table.

NexImmune Inc Insider Transactions

No Available Data

Sol J Barer Mailing Address

Above is the net worth, insider trading, and ownership report for Sol J Barer. You might contact Sol J Barer via mailing address: C/o Inspiremd, Inc., 321 Columbus Avenue, Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.